Aligos Therapeutics, Inc. (ALGS)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$5.51−$0.0400 (−0.72%) on the dayAs of the close; data may be delayed.
ALGS price, last 12 months
Key stats
- Previous close
- $5.55
- Open
- $5.70
- Day range
- $5.47 – $5.77
- 52-week range
- $3.98 – $13.69
- Volume
- 45K
- Avg volume (20 days)
- 51.3K
- Market cap
- $34.4M
Performance
1W+5.2%
1M−26.6%
3M−1.1%
6M−21.7%
YTD−40.9%
1Y−48.7%
vs S&P 500, 1Y−65.5 pts
Technicals and fundamentals
About Aligos Therapeutics, Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $34.4M